country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-19188

Copy Link Print Information

GL-331

GL-331 is a potent anti-cancer agent. GL-331 has demonstrated more efficacious anti-cancer activity in both the in vitro and in vivo lymphoma systems.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 127882-73-9
Formel: C₂₇H₂₄N₂O₉
Molecular Weight:520.49

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (274 KB)

GL-331 Chemical Structure

CAS. Nr.: 127882-73-9

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

GL-331 is a potent anti-cancer agent. GL-331 has demonstrated more efficacious anti-cancer activity in both the in vitro and in vivo lymphoma systems^[1].

Cellular Effect

Cell Line	Type	Value	Description	References
1A9	ED₅₀	<1.6 μM Compound: 6	Effective dose of compound against replication of 1A9 cell line was evaluated Effective dose of compound against replication of 1A9 cell line was evaluated	[PMID: 15006408]
A549	ED₅₀	<0.1 μM Compound: 6	Effective dose of compound against replication of A549 cell line was evaluated Effective dose of compound against replication of A549 cell line was evaluated	[PMID: 15006408]
A549	IC₅₀	0.113 μg/mL Compound: GL-331	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 22658864]
A549	IC₅₀	15.8 nM Compound: Ref 34, Cpd 4	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 32992133]
CAKI-1	ED₅₀	1.5 mM Compound: GL331	The compound was tested for tumor cell growth inhibitory activity against human renal cancer(CAKI-1) cell line The compound was tested for tumor cell growth inhibitory activity against human renal cancer(CAKI-1) cell line	[PMID: 10395485]
DU-145	IC₅₀	0.8 μg/mL Compound: GL-331	Cytotoxicity against human DU145 cells by SRB assay Cytotoxicity against human DU145 cells by SRB assay	[PMID: 22658864]
H9	EC₅₀	<0.00128 μM Compound: 15	Evaluation for anti-HIV activity using T cell line (H9). Evaluation for anti-HIV activity using T cell line (H9).	10.1016/S0960-894X(97)10108-1
H9	IC₅₀	0.07 μM Compound: 15	Cytotoxicity against H9 cell line Cytotoxicity against H9 cell line	10.1016/S0960-894X(97)10108-1
HCT-8	ED₅₀	1.6 μM Compound: 6	Effective dose of compound against replication of HCT-8 cell line was evaluated Effective dose of compound against replication of HCT-8 cell line was evaluated	[PMID: 15006408]
HCT-8	ED₅₀	8.5 mM Compound: GL331	The compound was tested for tumor cell growth inhibitory activity against human ileocecal carcinoma (HCT-8) cell line The compound was tested for tumor cell growth inhibitory activity against human ileocecal carcinoma (HCT-8) cell line	[PMID: 10395485]
HOS	ED₅₀	<1.6 μM Compound: 6	Effective dose of compound against replication of HOS cell line was evaluated Effective dose of compound against replication of HOS cell line was evaluated	[PMID: 15006408]
KB	ED₅₀	0.2 μg/mL Compound: 6	Dose required to cause reduction in human nasopharyngeal KB cancer cells after 3 days incubation Dose required to cause reduction in human nasopharyngeal KB cancer cells after 3 days incubation	[PMID: 15456257]
KB	ED₅₀	0.2 μg/mL Compound: 63, NSC-628679	Cytotoxicity against human KB cells after 72 hrs by MTT assay Cytotoxicity against human KB cells after 72 hrs by MTT assay	[PMID: 20187635]
KB	ED₅₀	0.49 mM Compound: GL331	The compound was tested for tumor cell growth inhibitory activity against human nasopharynx carcinoma(KB) cell line. The compound was tested for tumor cell growth inhibitory activity against human nasopharynx carcinoma(KB) cell line.	[PMID: 10395485]
KB	ED₅₀	1.5 μM Compound: 4	Effective dose required for inhibition of KB-7d cell replication after 3 days of continuous treatment Effective dose required for inhibition of KB-7d cell replication after 3 days of continuous treatment	[PMID: 15125972]
KB	ED₅₀	1.5 μM Compound: 6	Effective dose of compound against replication of KB/7d cell line was evaluated Effective dose of compound against replication of KB/7d cell line was evaluated	[PMID: 15006408]
KB	ED₅₀	2 μg/mL Compound: 6	Dose required for reduction in human nasopharyngeal KB-7d cancer cells after 3 days incubation Dose required for reduction in human nasopharyngeal KB-7d cancer cells after 3 days incubation	[PMID: 15456257]
KB	ED₅₀	3.5 μM Compound: 6	Effective dose of compound against replication of KB cell line was evaluated Effective dose of compound against replication of KB cell line was evaluated	[PMID: 15006408]
KB	ED₅₀	4.1 μM Compound: 6	Effective dose of compound against replication of KB-Vin cell line was evaluated Effective dose of compound against replication of KB-Vin cell line was evaluated	[PMID: 15006408]
KB	IC₅₀	0.032 μM Compound: 1	Growth inhibitory activity (antiproliferative) against KB cell lines Growth inhibitory activity (antiproliferative) against KB cell lines	[PMID: 8691469]
KB	IC₅₀	0.49 μM Compound: 63, NSC-628679	Cytotoxicity against human KB cells after 72 hrs by MTT assay Cytotoxicity against human KB cells after 72 hrs by MTT assay	[PMID: 20187635]
KB	IC₅₀	0.49 μM Compound: 15	Concentration required for 50% reduction in KB cell number after 3-day incubation Concentration required for 50% reduction in KB cell number after 3-day incubation	[PMID: 1312600]
KB	IC₅₀	0.49 μM Compound: 32	Concentration required for 50% reduction in KB cell number after 3-day incubation Concentration required for 50% reduction in KB cell number after 3-day incubation	[PMID: 1312601]
KB	IC₅₀	0.55 μM Compound: 1	Growth inhibitory activity (antiproliferative) against KB/7d cell lines Growth inhibitory activity (antiproliferative) against KB/7d cell lines	[PMID: 8691469]
KB	IC₅₀	0.819 μg/mL Compound: GL-331	Cytotoxicity against human KB cells by SRB assay Cytotoxicity against human KB cells by SRB assay	[PMID: 22658864]
KB	IC₅₀	3 μM Compound: 63, NSC-628679	Cytotoxicity against human vincristine-resistant KB cells after 72 hrs by MTT assay Cytotoxicity against human vincristine-resistant KB cells after 72 hrs by MTT assay	[PMID: 20187635]
MCF7	ED₅₀	24.5 μM Compound: 6	Effective dose of compound against replication of MCF-7 cell line was evaluated Effective dose of compound against replication of MCF-7 cell line was evaluated	[PMID: 15006408]
MCF7	ED₅₀	28.5 mM Compound: GL331	The compound was tested for tumor cell growth inhibitory activity against human breast cancer (MCF-7) cell line. The compound was tested for tumor cell growth inhibitory activity against human breast cancer (MCF-7) cell line.	[PMID: 10395485]
MCF7	IC₅₀	15.8 nM Compound: Ref 34, Cpd 4	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 32992133]
PC-3	ED₅₀	8.9 μM Compound: 6	Effective dose of compound against replication of PC-3 cell line was evaluated Effective dose of compound against replication of PC-3 cell line was evaluated	[PMID: 15006408]
PC-3	IC₅₀	15.8 nM Compound: Ref 34, Cpd 4	Antiproliferative activity against human PC3 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human PC3 cells incubated for 72 hrs by MTT assay	[PMID: 32992133]
SK-MEL-2	ED₅₀	16.5 mM Compound: GL331	The compound was tested for tumor cell growth inhibitory activity against human melanoma (SKMEL-2) cell line. The compound was tested for tumor cell growth inhibitory activity against human melanoma (SKMEL-2) cell line.	[PMID: 10395485]
SK-MEL-2	ED₅₀	3 μM Compound: 6	Effective dose of compound against replication of SK-MEL-2 cell line was evaluated Effective dose of compound against replication of SK-MEL-2 cell line was evaluated	[PMID: 15006408]
U-373MG ATCC	IC₅₀	1 nM Compound: 42; GL331	Inhibition of HIF-1alpha in human U373 cells Inhibition of HIF-1alpha in human U373 cells	[PMID: 30682255]
U-87MG ATCC	ED₅₀	5.5 μM Compound: 6	Effective dose of compound against replication of U87MG cell line was evaluated Effective dose of compound against replication of U87MG cell line was evaluated	[PMID: 15006408]

In Vitro

GL-331 shows more efficacy than VP-16 (HY-13629) in killing cancer cells. GL-331 possesses more cell-killing activity even in MDR-1-overexpressing cell lines such as HCC36 and SW620. Its higher cytotoxicity can be attributed by the elevated ability to induce apoptotic cell death^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 127882-73-9
Molecular Weight 520.49
Formel C₂₇H₂₄N₂O₉
SMILES

O=C1OC[C@]2([H])[C@H](NC3=CC=C([N+]([O-])=O)C=C3)C4=C(C=C5OCOC5=C4)[C@@H](C6=CC(OC)=C(O)C(OC)=C6)[C@]21[H]
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. You Y. Podophyllotoxin derivatives: current synthetic approaches for new anticancer agents. Curr Pharm Des. 2005;11(13):1695-717. [Content Brief]

[2]. Huang TS, et al. A novel podophyllotoxin-derived compound GL331 is more potent than its congener VP-16 in killing refractory cancer cells. Pharm Res. 1999 Jul;16(7):997-1002. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen